Nemorexant (ACT-541468) |
| Catalog No.GC30941 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1505484-82-1
Sample solution is provided at 25 µL, 10mM.
Nemorexant (ACT-541468) is a potent orexin receptor antagonist extracted from patent WO2015083094A1, compound example 7, has IC50s of 2 nM and 3 nM for Ox1 receptor and Ox2 receptor, respectively.
Nemorexant (Compound example 7) is a orexin receptor antagonist with IC50s of 2 nM and 3 nM for Ox1 receptor and Ox2 receptor, respectively[1].
[1]. BOSS, Christoph, et al. USE OF BENZIMIDAZOLE-PROLINE DERIVATIVES. WO2015083094A1.
|
Cell experiment: |
Chinese hamster ovary (CHO) cells expressing the human orexin-1 receptor and the human orexin-2 receptor, respectively, are grown in culture medium (Ham F-12 with L-Glutamine) containing 300 μg/mL G418, 100 U/mL Penicillin, 100 μg/mL Streptomycin and 10 % heat inactivated fetal calf serum (FCS). The cells are seeded at 20,000 cells / well into 384-well black clear bottom sterile plates. The seeded plates are incubated overnight at 37°C in 5% CO2. Human orexin-A as an agonist is prepared as 1 mM stock solution in MeOH: water (1 :1), diluted in HBSS containing 0.1 % bovine serum albumin (BSA), NaHCO3: 0.375g/L and 20 mM HEPES for use in the assay at a final concentration of 3 nM. Antagonists are prepared as 10 mM stock solution in DMSO, then diluted in 384-well plates using DMSO followed by a transfer of the dilutions into in HBSS containing 0.1 % bovine serum albumin (BSA), NaHCO3: 0.375g/L and 20 mM HEPES. On the day of the assay, 50 μL of staining buffer (HBSS containing 1 % FCS, 20 mM HEPES, NaHCO3: 0.375g/L, 5 mM probenecid and 3 μM of the fluorescent calcium indicator fluo-4 AM (1 mM stock solution in DMSO, containing 10% pluronic) is added to each well. The 384-well cell-plates are incubated for 50 min at 37°C in 5% CO2 followed by equilibration at RT for 30 min before measurement. Within the Fluorescent Imaging Plate Reader, antagonists are added to the plate in a volume of 10 μL/well, incubated for 120 min and finally 10 μL/well of agonist is added. Fluorescence is measured for each well at 1 second intervals, and the height of each fluorescence peak is compared to the height of the fluorescence peak induced by an approximate EC70 (for example 5 nM) of orexin-A with vehicle in place of antagonist. The IC50 value is determined[1]. |
|
References: [1]. BOSS, Christoph, et al. USE OF BENZIMIDAZOLE-PROLINE DERIVATIVES. WO2015083094A1. |
|
| Cas No. | 1505484-82-1 | SDF | |
| Canonical SMILES | C[C@](CCC1)(C2=NC3=CC=C(Cl)C(C)=C3N2)N1C(C4=C(N5N=CC=N5)C=CC(OC)=C4)=O | ||
| Formula | C23H23ClN6O2 | M.Wt | 450.92 |
| Solubility | DMSO : ≥ 250 mg/mL (554.42 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2177 mL | 11.0884 mL | 22.1769 mL |
| 5 mM | 443.5 μL | 2.2177 mL | 4.4354 mL |
| 10 mM | 221.8 μL | 1.1088 mL | 2.2177 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 8 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *















